Coherus Oncology Inc at Morgan Stanley Global Healthcare Conference Transcript
Afternoon, everybody. Thanks for joining us here for the next session. Really pleased to have Coherus with us. I'm going to turn it over to Denny to make some opening comments, and then we can jump into Q&A.
Thank you very much, Matt, and thank you for the opportunity to speak at your conference this afternoon. So Coherus is about the business of overcoming immune resistance in cancer. And we do this, I think, with three of our products, which are very interesting. First of all, of course, we have a next-generation PD-1, toripalimab, brand name LOQTORZI, which we launched into NPC, which is moving along quite well. This has demonstrated differential activity against Keytruda in a number of settings, and we're, I think, the primarily, the NPC market has shown some very strong six-year survival data there and good positioning on the NCCN guidelines.
However, in terms of the pipeline, we're very, very excited about tagmokitug, which is a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
